Is metformin bad for kidneys
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
The Impact of Metformin on Kidney Health: A Comprehensive Review
Introduction to Metformin and Kidney Health
Metformin is a widely used oral antihyperglycemic agent primarily prescribed for managing type 2 diabetes mellitus (T2DM). Its primary mechanism involves the activation of AMP-activated protein kinase (AMPK), which plays a crucial role in cellular energy homeostasis. Beyond its glucose-lowering effects, recent research has explored metformin's potential benefits and risks concerning kidney health.
Renoprotective Effects of Metformin
Acute and Chronic Kidney Disease
Several studies have highlighted metformin's protective effects on the kidneys in both acute kidney injury (AKI) and chronic kidney disease (CKD). Metformin has been shown to protect renal tubular cells from inflammation, apoptosis, and oxidative stress in various animal models of AKI . Additionally, in CKD, metformin alleviates podocyte loss, mesangial cell apoptosis, and tubular cell senescence through AMPK-mediated pathways .
Diabetic Kidney Disease
In diabetic kidney disease (DKD), metformin has demonstrated significant renoprotective effects by suppressing renal inflammation, oxidative stress, and fibrosis. Clinical studies have associated metformin use with reduced mortality rates, cardiovascular disease, and progression to end-stage renal disease (ESRD) in T2DM patients with CKD. However, caution is advised due to the potential risk of lactic acidosis in patients with advanced CKD.
Polycystic Kidney Disease and Other Renal Conditions
Metformin also shows promise in treating autosomal dominant polycystic kidney disease (ADPKD) by inhibiting cyst formation and fluid secretion through AMPK activation. Furthermore, metformin has been found to alleviate urolithiasis and renal cell carcinoma (RCC).
Risks and Concerns
Metformin-Associated Lactic Acidosis (MALA)
One of the primary concerns with metformin use in patients with kidney disease is the risk of metformin-associated lactic acidosis (MALA). This condition is characterized by increased lactate generation and accumulation due to impaired lactate metabolism, which can lead to severe metabolic acidosis and adverse outcomes . Regulatory agencies, including the FDA, have issued warnings and restrictions on metformin use in patients with impaired renal function to mitigate this risk.
Clinical Data and Real-World Evidence
While preclinical studies and some clinical trials suggest beneficial effects of metformin on kidney health, real-world data present a more nuanced picture. For instance, a study from Taiwan indicated a higher adjusted mortality rate in metformin users with advanced CKD compared to non-users, highlighting the need for careful patient selection and monitoring. Conversely, other studies have shown that metformin use is associated with lower risks of all-cause mortality and cardiovascular events in patients with mild to moderate CKD .
Conclusion
Metformin exhibits significant renoprotective effects in various kidney diseases, including AKI, CKD, DKD, and ADPKD, primarily through AMPK activation and reduction of oxidative stress and inflammation. However, the risk of lactic acidosis, particularly in patients with advanced CKD, necessitates cautious use and adherence to regulatory guidelines. Further large-scale randomized controlled trials are essential to fully elucidate the benefits and risks of metformin in patients with different stages of kidney disease.
Sources and full results
Most relevant research papers on this topic